2.1 Important Dosage and Administration Instructions

Monitor patients closely for respiratory depression when initiating therapy and following dosage increases with Remifentanil Hydrochloride for injection and adjust the dosage accordingly [see Warnings and Precautions (5.2)].

Remifentanil Hydrochloride for injection is for IV use only. Continuous infusions of Remifentanil Hydrochloride for injection should be administered only by an infusion device. The injection site should be close to the venous cannula and all IV tubing should be cleared at the time of discontinuation of infusion.

Remifentanil Hydrochloride for injection should not be administered without dilution.

Consider an alternative to Remifentanil Hydrochloride for injection for patients taking mixed agonist/antagonist and partial agonist opioid analgesics due to reduced analgesic effect or potential withdrawal symptoms. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment. Discontinue Remifentanil Hydrochloride for injection if patient is not responding appropriately to treatment.

Discard unused portion.

2.2 General Anesthesia

Remifentanil Hydrochloride for injection is not recommended as the sole agent in general anesthesia because loss of consciousness cannot be assured and because of a high incidence of apnea, muscle rigidity, and tachycardia. Remifentanil Hydrochloride for injection is synergistic with other anesthetics; therefore, clinicians may need to reduce doses of thiopental, propofol, isoflurane, and midazolam by up to 75% with the coadministration of Remifentanil Hydrochloride for injection. The administration of Remifentanil Hydrochloride for injection must be individualized based on the patient's response.

2.3 Continuation as an Analgesic into the Immediate Postoperative Period Under the Direct Supervision of an Anesthesia Practitioner

Infusions of Remifentanil Hydrochloride for injection may be continued into the immediate postoperative period for select patients for whom later transition to longer acting analgesics may be desired.

• Remifentanil Hydrochloride for injection has not been studied in pediatric patients for use in the immediate postoperative period.
• The use of bolus injections of Remifentanil Hydrochloride for injection to treat pain during the postoperative period is not recommended.
• When used as an IV analgesic in the immediate postoperative period, Remifentanil Hydrochloride for injection should be initially administered by continuous infusion at a rate of 0.1 mcg/kg/min.
• The infusion rate may be adjusted every 5 minutes in 0.025 mcg/kg/min increments to balance the patient's level of analgesia and respiratory rate.
• Infusion rates greater than 0.2 mcg/kg/min are associated with respiratory depression (respiratory rate less than 8 breaths/min).

Due to the rapid offset of action of Remifentanil Hydrochloride for injection, no residual analgesic activity will be present within 5 to 10 minutes after discontinuation. For patients undergoing surgical procedures where postoperative pain is generally anticipated, alternative analgesics should be administered prior to discontinuation of Remifentanil Hydrochloride for injection. The choice of analgesic should be appropriate for the patient's surgical procedure and the level of follow-up care [see Clinical Studies (14)].

2.4 Analgesic Component of Monitored Anesthesia Care

It is strongly recommended that supplemental oxygen be supplied to the patient whenever Remifentanil Hydrochloride for injection is administered.

• Remifentanil Hydrochloride for injection has not been studied for use in children in monitored anesthesia care.

2.5 Discontinuation

Upon discontinuation of Remifentanil Hydrochloride for injection, the IV tubing should be cleared to prevent the inadvertent administration of Remifentanil Hydrochloride for injection at a later time.

For patients undergoing surgical procedures where postoperative pain is generally anticipated, alternative analgesics should be administered prior to discontinuation of Remifentanil Hydrochloride for injection. The choice of analgesic should be appropriate for the patient's surgical procedure and the level of follow-up care [see Clinical Studies (14)].

2.6 Dosage Modifications in Geriatric Patients

The starting doses of Remifentanil Hydrochloride for injection should be decreased by 50% in elderly patients (> 65 years). Remifentanil Hydrochloride for injection should then be cautiously titrated to effect [see Use in Specific Populations (8.5)].

2.7 Dosage Modifications in Pediatric Patients

See Table 2 for dosing recommendations for use of Remifentanil Hydrochloride for injection in pediatric patients from birth to 12 years of age for maintenance of anesthesia. [See Clinical Pharmacology: Specific Populations: Pediatric Population (12.3) and Dosage and Administration, Table 2 and Maintenance of Anesthesia (2.2).]

Remifentanil Hydrochloride for injection has not been studied in pediatric patients for use in the immediate postoperative period or for use as a component of monitored anesthesia care.

2.8 Dosage Modifications in Coronary Artery Bypass Surgery

Table 4 summarizes the recommended doses for induction, maintenance, and continuation as an analgesic into the ICU in adult patients, predominantly ASA physical status III or IV. To avoid hypotension during the induction phase, it is important to consider the concomitant medication regimens. [See Clinical Studies: Coronary Artery Bypass Surgery (14.5).]

2.9 Dosage Modifications in Obese Patients

The starting doses of Remifentanil Hydrochloride for injection should be based on ideal body weight (IBW) in obese patients (greater than 30% over their IBW) [see Use in Specific Populations (8.6)].

2.10 Dosage Modifications in Preanesthetic Medication

The need for premedication and the choice of anesthetic agents must be individualized. In clinical studies, patients who received Remifentanil Hydrochloride for injection frequently received a benzodiazepine premedication.

2.11 Preparation for Administration

To reconstitute solution, add 1 mL of diluent per mg of remifentanil. Shake well to dissolve. When reconstituted as directed, the solution contains approximately 1 mg of remifentanil activity per 1 mL.

• Remifentanil Hydrochloride for injection should be diluted to a recommended final concentration of 20, 25, 50, or 250 mcg/mL prior to administration (see Table 5). Remifentanil Hydrochloride for injection should not be administered without dilution.

Continuous IV infusions of Remifentanil Hydrochloride for injection should be administered only by an infusion device. Infusion rates of Remifentanil Hydrochloride for injection can be individualized for each patient using Table 6:

When Remifentanil Hydrochloride for injection is used as an analgesic component of monitored analgesia care, a final concentration of 25 mcg/mL is recommended. When Remifentanil Hydrochloride for injection is used for pediatric patients 1 year of age and older, a final concentration of 20 or 25 mcg/mL is recommended. Table 7 is a guideline for milliliter-per-hour delivery for a solution of 20 mcg/mL with an infusion device.

Table 8 is a guideline for milliliter-per-hour delivery for a solution of 25 mcg/mL with an infusion device.

Table 9 is a guideline for milliliter-per-hour delivery for a solution of 50 mcg/mL with an infusion device.

Table 10 is a guideline for milliliter-per-hour delivery for a solution of 250 mcg/mL with an infusion device.

2.12 Compatibility and Stability

5.1 Addiction, Abuse, and Misuse

Remifentanil Hydrochloride for injection contains remifentanil, a Schedule II controlled substance. As an opioid, Remifentanil Hydrochloride for injection exposes users to the risks of addiction, abuse, and misuse [see Drug Abuse and Dependence (9)].

Opioids are sought for nonmedical use and are subject to diversion from legitimate prescribed use. Consider these risks when handling Remifentanil Hydrochloride for injection. Strategies to reduce these risks include proper product storage and control practices for a C-II drug. Contact local state professional licensing board or state controlled substances authority for information on how to prevent and detect abuse or diversion of this product.

5.2 Life-Threatening Respiratory Depression

Serious, life-threatening, or fatal respiratory depression has been reported with the use of opioids, even when used as recommended. Respiratory depression, if not immediately recognized and treated, may lead to respiratory arrest and death.

Remifentanil Hydrochloride for injection should be administered only by persons specifically trained in the use of anesthetic drugs and the management of the respiratory effects of potent opioids, including respiration and cardiac resuscitation of patients in the age group being treated. Such training must include the establishment and maintenance of a patent airway and assisted ventilation. Resuscitative and intubation equipment, oxygen, and opioid antagonists must be readily available.

Respiratory depression in spontaneously breathing patients is generally managed by decreasing the rate of the infusion of Remifentanil Hydrochloride for injection by 50% or by temporarily discontinuing the infusion [see Overdosage (10)].

Carbon dioxide (CO2) retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids. While serious, life-threatening, or fatal respiratory depression can occur at any time during the use of Remifentanil Hydrochloride for injection, the risk is greatest during the initiation of therapy or following a dosage increase. Monitor patients closely for respiratory depression, especially when initiating therapy with and following dosage increases of Remifentanil Hydrochloride for injection.

Remifentanil Hydrochloride for injection should not be used in diagnostic or therapeutic procedures outside the monitored anesthesia care setting. Patients receiving monitored anesthesia care should be continuously monitored by persons not involved in the conduct of the surgical or diagnostic procedure. Oxygen saturation should be monitored on a continuous basis.

Patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with a substantially decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression are at increased risk of decreased respiratory drive including apnea, even at recommended dosages of Remifentanil Hydrochloride for injection. Elderly, cachectic, or debilitated patients may have altered pharmacokinetics or altered clearance compared to younger, healthier patients resulting in greater risk for respiratory depression. Monitor such patients closely including vital signs, particularly when initiating and titrating Remifentanil Hydrochloride for injection and when Remifentanil Hydrochloride for injection is given concomitantly with other drugs that depress respiration. To reduce the risk of respiratory depression, proper dosing and titration of Remifentanil Hydrochloride for injection are essential [see Dosage and Administration (2.11)].

5.3 Risks from Use as Postoperative Analgesia with Concomitant Benzodiazepines or Other CNS Depressants

When benzodiazepines or other CNS depressants are used with Remifentanil Hydrochloride for injection, pulmonary arterial pressure may be decreased. This fact should be considered by those who conduct diagnostic and surgical procedures where interpretation of pulmonary arterial pressure measurements might determine final management of the patient. When high dose or anesthetic dosages of Remifentanil Hydrochloride for injection are employed, even relatively small dosages of diazepam may cause cardiovascular depression. 

When Remifentanil Hydrochloride for injection is used with CNS depressants, hypotension can occur. If it occurs, consider the possibility of hypovolemia and manage with appropriate parenteral fluid therapy. When operative conditions permit, consider repositioning the patient to improve venous return to the heart. Exercise care in moving and repositioning of patients because of the possibility of orthostatic hypotension. If volume expansion with fluids plus other countermeasures do not correct hypotension, consider administration of pressor agents other than epinephrine. Epinephrine may paradoxically decrease blood pressure in patients treated with a neuroleptic that blocks alpha adrenergic activity. 

Hypotension, profound sedation, respiratory depression, coma, and death may result from the concomitant use of Remifentanil Hydrochloride for injection with benzodiazepines and/or other CNS depressants, including alcohol (e.g., non-benzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids). Patients should be advised to avoid alcohol for 24 hours after surgery [see Drug Interactions (7)]. 

Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioid analgesics alone. Because of similar pharmacological properties, it is reasonable to expect similar risk with the concomitant use of other CNS depressant drugs with opioid analgesics [see Drug Interactions (7)]. 

If the decision is made to manage postoperative pain with Remifentanil Hydrochloride for injection concomitantly with a benzodiazepine or other CNS depressant, start dosing with the lowest effective dosage and titrate based on clinical response. Monitor patients closely for signs and symptoms of respiratory depression, sedation, and hypotension. Fluids or other measures to counter hypotension should be available [see Drug Interactions (7)]. 

5.4 Opioid-Induced Hyperalgesia and Allodynia

Opioid-Induced Hyperalgesia (OIH) occurs when an opioid analgesic paradoxically causes an increase in pain, or an increase in sensitivity to pain. This condition differs from tolerance, which is the need for increasing doses of opioids to maintain a defined effect [see Dependence (9.3)]. Symptoms of OIH include (but may not be limited to) increased levels of pain upon opioid dosage increase, decreased levels of pain upon opioid dosage decrease, or pain from ordinarily non-painful stimuli (allodynia). These symptoms may suggest OIH only if there is no evidence of underlying disease progression, opioid tolerance, opioid withdrawal, or addictive behavior.

Cases of OIH have been reported, both with short-term and longer-term use of opioid analgesics. Though the mechanism of OIH is not fully understood, multiple biochemical pathways have been implicated. Medical literature suggests a strong biologic plausibility between opioid analgesics and OIH and allodynia. If a patient is suspected to be experiencing OIH, carefully consider appropriately decreasing the dose of the current opioid analgesic or opioid rotation (safely switching the patient to a different opioid moiety) [see Dosage and Administration (2), Warnings and Precautions (5.2)].

5.5 Serotonin Syndrome with Concomitant Use of Serotonergic Drugs

Cases of serotonin syndrome, a potentially life-threatening condition, have been reported during concomitant use of Remifentanil Hydrochloride for injection with serotonergic drugs. Serotonergic drugs include selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonergic neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), and drugs that impair metabolism of serotonin (including MAO inhibitors, both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue) [see Drug Interactions (7)]. This may occur within the recommended dosage range.

Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination, rigidity), and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). The onset of symptoms generally occurs within several hours to a few days of concomitant use, but may occur later than that. Discontinue Remifentanil Hydrochloride for injection if serotonin syndrome is suspected.

5.6 Administration

Continuous infusions of Remifentanil Hydrochloride for injection should be administered only by an infusion device. IV bolus administration of Remifentanil Hydrochloride for injection should be used only during the maintenance of general anesthesia. In nonintubated patients, single doses of Remifentanil Hydrochloride for injection should be administered over 30 to 60 seconds.

Interruption of an infusion of Remifentanil Hydrochloride for injection will result in rapid offset of effect. Rapid clearance and lack of drug accumulation result in rapid dissipation of respiratory depressant and analgesic effects upon discontinuation of Remifentanil Hydrochloride for injection at recommended doses. Discontinuation of an infusion of Remifentanil Hydrochloride for injection should be preceded by the establishment of adequate postoperative analgesia.

Injections of Remifentanil Hydrochloride for injection should be made into IV tubing at or close to the venous cannula. Upon discontinuation of Remifentanil Hydrochloride for injection, the IV tubing should be cleared to prevent the inadvertent administration of Remifentanil Hydrochloride for injection at a later point in time. Failure to adequately clear the IV tubing to remove residual Remifentanil Hydrochloride for injection has been associated with the appearance of respiratory depression, apnea, and muscle rigidity upon the administration of additional fluids or medications through the same IV tubing.

5.7 Skeletal Muscle Rigidity

Skeletal muscle rigidity can be caused by Remifentanil Hydrochloride for injection and is related to the dose and speed of administration. Remifentanil Hydrochloride for injection may cause chest wall rigidity (inability to ventilate) after single doses of > 1 mcg/kg administered over 30 to 60 seconds, or after infusion rates > 0.1 mcg/kg/min. Single doses < 1 mcg/kg may cause chest wall rigidity when given concurrently with a continuous infusion of Remifentanil Hydrochloride for injection.

Muscle rigidity induced by Remifentanil Hydrochloride for injection should be managed in the context of the patient's clinical condition. Muscle rigidity occurring during the induction of anesthesia should be treated by the administration of a neuromuscular blocking agent and the concurrent induction medications and can be treated by decreasing the rate or discontinuing the infusion of Remifentanil Hydrochloride for injection or by administering a neuromuscular blocking agent. The neuromuscular blocking agents used should be compatible with the patient's cardiovascular status.

Muscle rigidity seen during the use of Remifentanil Hydrochloride for injection in spontaneously breathing patients may be treated by stopping or decreasing the rate of administration of Remifentanil Hydrochloride for injection. Resolution of muscle rigidity after discontinuing the infusion of Remifentanil Hydrochloride for injection occurs within minutes. In the case of life-threatening muscle rigidity, a rapid onset neuromuscular blocker or naloxone may be administered.

5.8 Potential Inactivation by Nonspecific Esterases in Blood Products

Remifentanil Hydrochloride for injection should not be administered into the same IV tubing with blood due to potential inactivation by nonspecific esterases in blood products.

5.9 Bradycardia

Bradycardia has been reported with Remifentanil Hydrochloride for injection and is responsive to ephedrine or anticholinergic drugs, such as atropine and glycopyrrolate.

5.10 Hypotension

Hypotension has been reported with Remifentanil Hydrochloride for injection and is responsive to decreases in the administration of Remifentanil Hydrochloride for injection or to IV fluids or catecholamine (ephedrine, epinephrine, norepinephrine, etc.) administration.

5.11 Intraoperative Awareness

Intraoperative awareness has been reported in patients under 55 years of age when Remifentanil Hydrochloride for injection has been administered with propofol infusion rates of ≤ 75 mcg/kg/min.

5.12 Risks of Use in Spontaneously Breathing Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness

In patients who may be susceptible to the intracranial effects of CO2 retention (e.g., those with evidence of increased intracranial pressure or brain tumors), Remifentanil Hydrochloride for injection may reduce respiratory drive, and the resultant CO2 retention can further increase intracranial pressure in spontaneously breathing patients. Monitor such patients for signs of sedation and respiratory depression, particularly when initiating therapy with Remifentanil Hydrochloride for injection.

Opioids may also obscure the clinical course in a patient with a head injury.

5.13 Risks of Use in Patients with Biliary Tract Disease

The remifentanil in Remifentanil Hydrochloride for injection may cause spasm of the sphincter of Oddi. Opioids may cause increases in serum amylase. Monitor patients with biliary tract disease, including acute pancreatitis, for worsening symptoms.

5.14 Increased Risk of Seizures in Patients with Seizure Disorders

The remifentanil in Remifentanil Hydrochloride for injection may increase the frequency of seizures in patients with seizure disorders, and may increase the risk of seizures occurring in other clinical settings associated with seizures. Monitor patients with a history of seizure disorders for worsened seizure control during Remifentanil Hydrochloride for injection therapy.

5.15 Rapid Offset of Action

Analgesic activity will subside within 5 to 10 minutes after discontinuation of administration of Remifentanil Hydrochloride for injection. However, respiratory depression may continue in some patients for up to 30 minutes after termination of infusion due to residual effects of concomitant anesthetics. Standard monitoring should be maintained in the postoperative period to ensure adequate recovery without stimulation. For patients undergoing surgical procedures where postoperative pain is generally anticipated, other analgesics should be administered prior to the discontinuation of Remifentanil Hydrochloride for injection.

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Adverse event information is derived from controlled clinical studies that were conducted in a variety of surgical procedures of varying duration, using a variety of premedications and other anesthetics, and in patient populations with diverse characteristics including underlying disease.

6.2 Postmarketing Experience

The following adverse reactions have been identified during post approval use of remifentanil. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Cardiovascular: Asystole

Serotonin syndrome: Cases of serotonin syndrome, a potentially life-threatening condition, have been reported during concomitant use of opioids with serotonergic drugs.

Anaphylaxis: Anaphylaxis has been reported with ingredients contained in Remifentanil Hydrochloride for injection.

Hyperalgesia and Allodynia: Cases of hyperalgesia and allodynia have been reported with opioid therapy of any duration [see Warnings and Precautions (5.4)].

Hypoglycemia: Cases of hypoglycemia have been reported in patients taking opioids. Most reports were in patients with at least one predisposing risk factor (e.g., diabetes).

8.1 Pregnancy

8.2 Lactation

8.4 Pediatric Use

The efficacy and safety of Remifentanil Hydrochloride for injection as an analgesic agent for use in the maintenance of general anesthesia in outpatient and inpatient pediatric surgery have been established in controlled clinical studies in pediatric patients from birth to 12 years [see Clinical Studies (14.4)].

The initial maintenance infusion regimen of Remifentanil Hydrochloride for injection evaluated in pediatric patients from birth to 2 months of age was 0.4 mcg/kg/min, the approved adult regimen for use with N2O. The clearance rate observed in neonates was highly variable and on average was 2 times higher than in the young healthy adult population. Therefore, while a starting infusion rate of 0.4 mcg/kg/min may be appropriate for some neonates, an increased infusion rate may be necessary to maintain adequate surgical anesthesia, and additional bolus doses may be required. The individual dose for each patient should be carefully titrated. [See Clinical Pharmacology: Specific Populations: Pediatric Population (12.3) and Dosage and Administration, Table 2 and Maintenance of Anesthesia (2.2).]

Remifentanil Hydrochloride for injection has not been studied in pediatric patients for use as a postoperative analgesic or as an analgesic component of monitored anesthesia care.

8.5 Geriatric Use

Respiratory depression is the chief risk for elderly patients treated with opioids and has occurred after large initial doses were administered to patients who were not opioid-tolerant or when opioids were co-administered with other agents that depress respiration. Titrate the dosage of Remifentanil Hydrochloride for injection slowly in geriatric patients and frequently reevaluate the patient for signs of central nervous system and respiratory depression [see Warnings and Precautions (5.2)].

Of the total number of subjects in clinical studies of Remifentanil Hydrochloride for injection, 486 were 65 and over (age range 66 to 90 years). While the effective biological half-life of remifentanil is unchanged, elderly patients have been shown to be twice as sensitive as the younger population to the pharmacodynamic effects of remifentanil. The recommended starting dose of Remifentanil Hydrochloride for injection should be decreased by 50% in patients over 65 years of age [see Clinical Pharmacology (12.3) and Dosage and Administration (2.2)]. Titrate the dosage of Remifentanil Hydrochloride for injection slowly in geriatric patients. [See Warnings and Precautions (5.5).]

The clearance of remifentanil is reduced (approximately 25%) in the elderly (> 65 years of age) compared to young adults (average 25 years of age). However, remifentanil blood concentrations fall as rapidly after termination of administration in the elderly as in young adults.

This drug is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

8.6 Use in Morbidly Obese Patients

As for all potent opioids, caution is required with use in morbidly obese patients because of alterations in cardiovascular and respiratory physiology [see Dosage and Administration (2.2)].

8.7 Long-Term Use in the ICU

No data are available on the long-term (longer than 16 hours) use of Remifentanil Hydrochloride for injection as an analgesic in ICU patients.

9.1 Controlled Substance

Remifentanil Hydrochloride for injection contains remifentanil, a Schedule II controlled substance.

9.2 Abuse

Remifentanil Hydrochloride for injection contains remifentanil, a substance with high potential for misuse and abuse, which can lead to the development of substance use disorder, including addiction [see Warnings and Precautions (5.1)].

Misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a healthcare provider or for whom it was not prescribed.

Abuse is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects.

Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence.

Misuse and abuse of Remifentanil Hydrochloride for injection increases risk of overdosage, which may lead to central nervous system and respiratory depression, hypotension, seizures, and death. The risk is increased with concurrent abuse of Remifentanil Hydrochloride for injection with alcohol and/or other CNS depressants. Abuse of and addiction to opioids in some individuals may not be accompanied by concurrent tolerance and symptoms of physical dependence. In addition, abuse of opioids can occur in the absence of addiction.

All patients treated with opioids require careful and frequent reevaluation for signs of misuse, abuse, and addiction, because use of opioid analgesic products carries the risk of addiction even under appropriate medical use. Patients at high risk of Remifentanil Hydrochloride for injection abuse include those with a history of prolonged use of any opioid, including products containing remifentanil, those with a history of drug or alcohol abuse, or those who use Remifentanil Hydrochloride for injection in combination with other abused drugs.

“Drug-seeking” behavior is very common in persons with substance use disorders. Drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing, or referral, repeated “loss” of prescriptions, tampering with prescriptions, and reluctance to provide prior medical records or contact information for other treating healthcare provider(s). “Doctor shopping” (visiting multiple prescribers to obtain additional prescriptions) is common among people who abuse drugs and people with substance use disorder. Preoccupation with achieving adequate pain relief can be appropriate behavior in a patient with inadequate pain control.

Remifentanil Hydrochloride for injection, like other opioids, can be diverted for nonmedical use into illicit channels of distribution. Careful record-keeping of prescribing information, including quantity, frequency, and renewal requests, as required by state and federal law, is strongly advised.

Proper assessment of the patient, proper prescribing practices, periodic reevaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs.

Risks Specific to Abuse of Remifentanil Hydrochloride for injection

Abuse of Remifentanil Hydrochloride for injection poses a risk of overdose and death. The risk is increased with concurrent use of Remifentanil Hydrochloride for injection with alcohol and/or other CNS depressants.

Parenteral drug abuse is commonly associated with transmission of infectious diseases such as hepatitis and HIV.

9.3 Dependence

Both tolerance and physical dependence can develop during use of opioid therapy. Tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose). Physical dependence is a state that develops as a result of a physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dosage reduction of a drug.

Withdrawal may be precipitated through the administration of drugs with opioid antagonist activity (e.g., naloxone), mixed agonist/antagonist analgesics (e.g., pentazocine, butorphanol, nalbuphine), or partial agonists (e.g., buprenorphine). Physical dependence may not occur to a clinically significant degree until after several days to weeks of continued use.

Remifentanil Hydrochloride for injection should not be abruptly discontinued in a physically-dependent patient [see Dosage and Administration (2)]. If Remifentanil Hydrochloride for injection is abruptly discontinued in a physically-dependent patient, a withdrawal syndrome may occur, typically characterized by restlessness, lacrimation, rhinorrhea, perspiration, chills, myalgia, and mydriasis. Other signs and symptoms also may develop, including irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased blood pressure, respiratory rate, or heart rate.

Infants born to mothers physically dependent on opioids will also be physically dependent and may exhibit respiratory difficulties and withdrawal signs [see Use in Specific Populations (8.1)]. 

12.1 Mechanism of Action

Remifentanil Hydrochloride for injection is a μ-opioid agonist with rapid onset and peak effect, and short duration of action. The μ- opioid activity of Remifentanil Hydrochloride for injection is antagonized by opioid antagonists such as naloxone.

Unlike other opioids, Remifentanil Hydrochloride for injection is rapidly metabolized by hydrolysis of the propanoic acid-methyl ester linkage by nonspecific blood and tissue esterases. Remifentanil Hydrochloride for injection is not a substrate for plasma cholinesterase (pseudocholinesterase) and, therefore, patients with atypical cholinesterase are expected to have a normal duration of action.

12.2 Pharmacodynamics

The analgesic effects of Remifentanil Hydrochloride for injection are rapid in onset and offset. Its effects and side effects are dose dependent and similar to other μ-opioids. Remifentanil Hydrochloride for injection in humans has a rapid blood-brain equilibration halftime of 1 ± 1 minutes (mean ± SD) and a rapid onset of action. The pharmacodynamic effects of Remifentanil Hydrochloride for injection closely follow the measured blood concentrations, allowing direct correlation between dose, blood levels, and response. Blood concentration decreases 50% in 3 to 6 minutes after a 1-minute infusion or after prolonged continuous infusion due to rapid distribution and elimination processes and is independent of duration of drug administration. Recovery from the effects of Remifentanil Hydrochloride for injection occurs rapidly (within 5 to 10 minutes). New steady-state concentrations occur within 5 to 10 minutes after changes in infusion rate. When used as a component of an anesthetic technique, Remifentanil Hydrochloride for injection can be rapidly titrated to the desired depth of anesthesia/analgesia (e.g., as required by varying levels of intraoperative stress) by changing the continuous infusion rate or by administering an IV bolus injection.

Respiration

Remifentanil Hydrochloride for injection depresses respiration in a dose-related fashion. Unlike other fentanyl analogs, the duration of action of Remifentanil Hydrochloride for injection at a given dose does not increase with increasing duration of administration, due to lack of drug accumulation. When Remifentanil Hydrochloride for injection and alfentanil were dosed to equal levels of respiratory depression, recovery of respiratory drive after 3-hour infusions was more rapid and less variable with Remifentanil Hydrochloride for injection (see Figure 1).

Figure 1: Recovery of Respiratory Drive After Equipotent* Doses of Remifentanil Hydrochloride for injection and Alfentanil Using CO2- Stimulated Minute Ventilation in Adult Volunteers (±1.5 SEM)

Spontaneous respiration occurs at blood concentrations of 4 to 5 ng/mL in the absence of other anesthetic agents; for example, after discontinuation of a 0.25 mcg/kg/min infusion of remifentanil, these blood concentrations would be reached in 2 to 4 minutes. In patients undergoing general anesthesia, the rate of respiratory recovery depends upon the concurrent anesthetic; N2O < propofol < isoflurane [see Clinical Studies: Recovery (14.2)].

12.3 Pharmacokinetics

After IV doses administered over 60 seconds, the pharmacokinetics of remifentanil fit a three compartment model with a rapid distribution half-life of one minute, a slower distribution half-life of 6 minutes, and a terminal elimination half-life of 10 to 20 minutes. Since the terminal elimination component contributes less than 10% of the overall area under the concentration versus time curve (AUC), the effective biological half-life of Remifentanil Hydrochloride for injection is 3 to 10 minutes. This is similar to the 3- to 10- minute half-life measured after termination of prolonged infusions (up to 4 hours; see Figure 2) and correlates with recovery times observed in the clinical setting after infusions up to 12 hours.

Concentrations of remifentanil are proportional to the dose administered throughout the recommended dose range. The pharmacokinetics of remifentanil are unaffected by the presence of renal or hepatic impairment.

Elimination

The clearance of remifentanil in young, healthy adults is approximately 40 mL/min/kg. Clearance generally correlates with total body weight (except in severely obese patients when it correlates better with IBW). The high clearance of remifentanil combined with a relatively small volume of distribution produces a short elimination half-life of approximately 3 to 10 minutes (see Figure 2). This value is consistent with the time taken for blood or effect site concentrations to fall by 50% (context-sensitive half-times) which is approximately 3 to 6 minutes. Unlike other fentanyl analogs, the duration of action does not increase with prolonged administration.

Figure 2: Mean Concentration (sd) versus Time

Titration to Effect

The rapid elimination of remifentanil permits the titration of infusion rate without concern for prolonged duration. In general, every 0.1 mcg/kg/min change in the IV infusion rate will lead to a corresponding 2.5 ng/mL change in blood remifentanil concentration within 5 to 10 minutes. In intubated patients only, a more rapid increase (within 3 to 5 minutes) to a new steady state can be achieved with a 1.0 mcg/kg bolus dose in conjunction with an infusion rate increase.

Metabolism

Remifentanil is an esterase-metabolized opioid. A labile ester linkage renders this compound susceptible to hydrolysis by nonspecific esterases in blood and tissues. This hydrolysis results in the production of the carboxylic acid metabolite (3-[4-methoxycarbonyl-4-[(1-oxopropyl)phenylamino]-1- piperidine]propanoic acid), and represents the principal metabolic pathway for remifentanil (> 95%).

The carboxylic acid metabolite is essentially inactive (1/4600 as potent as remifentanil in dogs). Remifentanil is not metabolized by plasma cholinesterase (pseudocholinesterase) and is not appreciably metabolized by the liver or lung.

Excretion

The carboxylic acid metabolite is excreted by the kidneys with an elimination half-life of approximately 90 minutes.

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14.1 Induction and Maintenance of General Anesthesia - Inpatient/Outpatient

The efficacy of Remifentanil Hydrochloride for injection was investigated in 1,562 patients in 15 randomized, controlled trials as the analgesic component for the induction and maintenance of general anesthesia. Eight of these studies compared Remifentanil Hydrochloride for injection to alfentanil and two studies compared Remifentanil Hydrochloride for injection to fentanyl. In these studies, doses of Remifentanil Hydrochloride for injection up to the ED90 were compared to recommended doses (approximately ED50) of alfentanil or fentanyl.

14.2 Recovery

In 2,169 patients receiving Remifentanil Hydrochloride for injection  for periods up to 16 hours, recovery from anesthesia was rapid, predictable, and independent of the duration of the infusion of Remifentanil Hydrochloride for injection. In the seven controlled, general surgery studies, extubation occurred in a median of 5 minutes (range: -3 to 17 minutes in 95% of patients) in outpatient anesthesia and 10 minutes (range: 0 to 32 minutes in 95% of patients) in inpatient anesthesia. Recovery in studies using nitrous oxide or propofol was faster than in those using isoflurane as the concurrent anesthetic. There was no case of remifentanil-induced delayed respiratory depression occurring more than 30 minutes after discontinuation of remifentanil [see Warnings and Precautions (5.15)].

In a double-blind, randomized study, administration of morphine sulfate (0.15 mg/kg) intravenously 20 minutes before the anticipated end of surgery to 98 patients did not delay recovery of respiratory drive in patients undergoing major surgery with remifentanil-propofol total IV anesthesia.

14.3 Spontaneous Ventilation Anesthesia

Two randomized, dose-ranging studies (n = 127) examined the administration of Remifentanil Hydrochloride for injection to outpatients undergoing general anesthesia with a laryngeal mask. Starting infusion rates of Remifentanil Hydrochloride for injection of ≤ 0.05 mcg/kg/min provided supplemental analgesia while allowing spontaneous ventilation with propofol or isoflurane. Bolus doses of Remifentanil Hydrochloride for injection during spontaneous ventilation lead to transient periods of apnea, respiratory depression, and muscle rigidity.

14.4 Pediatric Anesthesia

Remifentanil Hydrochloride for injection has been evaluated for maintenance of general anesthesia in 410 pediatric patients from birth to 12 years undergoing inpatient and outpatient procedures. Four clinical studies have been performed.

Study 1, an open-label, randomized, controlled clinical trial (n = 129), compared Remifentanil Hydrochloride for injection (n = 68) with alfentanil (n = 19), isoflurane (n = 22), or propofol (n = 20) in children 2 to 12 years of age undergoing strabismus surgery. After induction of anesthesia which included the administration of atropine, Remifentanil Hydrochloride for injection was administered as an initial infusion of 1 mcg/kg/min with 70% nitrous oxide. The infusion rate required during maintenance of anesthesia was 0.73 to 1.95 mcg/kg/min. Time to extubation and to purposeful movement was a median of 10 minutes (range 1 to 24 minutes).

Study 2, a double-blind, randomized, controlled trial (n = 222), compared Remifentanil Hydrochloride for injection (n = 119) to fentanyl (n = 103) in children 2 to 12 years of age undergoing tonsillectomy with or without adenoidectomy. After induction of anesthesia, patients received a 0.25 mcg/kg/min infusion of Remifentanil Hydrochloride for injection or fentanyl by IV bolus with nitrous oxide/oxygen (2:1) and either halothane or sevoflurane for maintenance of anesthesia. The mean infusion rate required during maintenance of anesthesia was 0.3 mcg/kg/min (range 0.2 to 1.3 mcg/kg/min). The continuous infusion rate was decreased to 0.05 mcg/kg/min approximately 10 minutes prior to the end of surgery. Time to spontaneous purposeful movement was a median of 8 minutes (range 1 to 19 minutes). Time to extubation was a median of 9 minutes (range 2 to 19 minutes).

Study 3, an open-label, randomized, controlled trial (n = 271), compared Remifentanil Hydrochloride for injection(n = 185) with a regional anesthetic technique (n = 86) in children 1 to 12 years of age undergoing major abdominal, urological, or orthopedic surgery. Patients received a 0.25 mcg/kg/min infusion of Remifentanil Hydrochloride for injection following a 1.0 mcg/kg bolus or bupivacaine by epidural infusion, along with isoflurane and nitrous oxide after the induction of anesthesia. The mean infusion rate required during maintenance of anesthesia was 0.25 mcg/kg/min (range 0 to 0.75 mcg/kg/min). Both treatments were effective in attenuating responses to skin incision during surgery. The hemodynamic profile of the Remifentanil Hydrochloride for injection group was consistent with an opioid-based general anesthetic technique. Time to spontaneous purposeful movement was a median of 15 minutes (range, 2 to 75 minutes) in the remifentanil group. Time to extubation was a median of 13 minutes (range, 4 to 31 minutes) in the remifentanil group.

Study 4, an open-label, randomized, controlled trial (n = 60), compared Remifentanil Hydrochloride for injection(n = 38) with halothane (n = 22) in ASA 1 or 2, full term neonates and infants ≤ 8 weeks of age weighing at least 2500 grams who were undergoing pyloromyotomy. After induction of anesthesia, which included the administration of atropine, patients received 0.4 mcg/kg/min of Remifentanil Hydrochloride for injection or 0.4% halothane with 70% nitrous oxide for initial maintenance of anesthesia and then both agents were adjusted according to clinical response. Bolus doses of 1 mcg/kg administered over 30 to 60 seconds were used to treat brief episodes of hypertension and tachycardia, and infusion rates were increased by 50% to treat sustained hypertension and tachycardia. The range of infusion rates of Remifentanil Hydrochloride for injection required during maintenance of anesthesia was 0.4 to 1 mcg/kg/min.

Seventy-one percent (71%) of Remifentanil Hydrochloride for injection patients required supplementary boluses or rate increases from the starting dose of 0.4 mcg/kg/min to treat hypertension, tachycardia, movement or somatic signs of light anesthesia. Twenty-four percent of the patients required an increase from the initial rate of 0.4 mcg/kg/min prior to incision and 26% of patients required an infusion rate between 0.8 and 1.0 mcg/kg/min, most often during gastric manipulation. The continuous infusion rate was decreased to 0.05 mcg/kg/min approximately 10 minutes before the end of surgery.

In the Remifentanil Hydrochloride for injection group, median time from discontinuation of anesthesia to spontaneous purposeful movement was 6.5 minutes (range, 1 to 13 minutes) and median time to extubation was 8.5 minutes (range, 1 to 14 minutes).

The initial maintenance infusion regimen of Remifentanil Hydrochloride for injection evaluated in pediatric patients from birth to 2 months of age was 0.4 mcg/kg/min, the approved adult regimen for use with N2O. The clearance rate observed in the neonatal population was highly variable and on average was two times higher than in the young healthy adult population. [See Clinical Pharmacology: Specific Populations: Pediatric Population (12.3) and Dosage and Administration, Table 2 (2.2).]

No pediatric patients receiving Remifentanil Hydrochloride for injection required naloxone during the immediate postoperative recovery period.

14.5 Coronary Artery Bypass Surgery

Remifentanil Hydrochloride for injection was originally administered to 225 subjects undergoing elective CABG surgery in two dose-ranging studies without active comparators. Subsequently, two double-blind, double-dummy clinical studies (N = 426) evaluated Remifentanil Hydrochloride for injection (n = 236) at recommended doses versus active comparators (n = 190).

The first comparator study, a multi-center, randomized, double-blind, double-dummy, parallel-group study (N = 369), compared Remifentanil Hydrochloride for injection (n = 201) with fentanyl (n = 168) in adult patients undergoing elective CABG surgery. Subjects received 1 to 3 mg midazolam and 0.05 mg/kg morphine IV as premedication. Anesthesia was induced with propofol 0.5 mg/kg (higher doses administered with Remifentanil Hydrochloride for injection were associated with excessive hypotension) over one minute plus 10-mg boluses every 10 seconds until loss of consciousness followed by either cisatracurium 0.2 mg/kg or vecuronium 0.15 mg/kg. Patients randomized to Remifentanil Hydrochloride for injection received a 1 mcg/kg/min infusion of Remifentanil Hydrochloride for injection followed by a placebo bolus administered over 3 minutes. In the active control group, a placebo IV infusion was started and a fentanyl bolus 10 mcg/kg was administered over 3 minutes. All subjects received isoflurane titrated initially to end tidal concentration of 0.5%. During maintenance, the group randomized to Remifentanil Hydrochloride for injection received as needed 0.5-1 mcg/kg/min IV rate increases (to a maximum of 4 mcg/kg/min) of Remifentanil Hydrochloride for injection and 1 mcg/kg IV boluses of Remifentanil Hydrochloride for injection. The active control group received 2 mcg/kg IV boluses of fentanyl and increases in placebo IV infusion rate.

The second comparator study, a multi-center, double-blind, randomized, parallel group study (N = 57), compared Remifentanil Hydrochloride for injection (n = 35) to fentanyl (n = 22) in adult patients undergoing elective CABG surgery with poor left ventricular function (ejection fraction < 0.35). Subjects received oral lorazepam 40 mcg/kg as premedication. Anesthesia was induced using etomidate until loss of consciousness, followed by a low-dose propofol infusion (3 mg/kg/hr) and pancuronium 0.15 mg/kg. Subjects in the group administered Remifentanil Hydrochloride for injection received a placebo bolus dose and a continuous infusion of Remifentanil Hydrochloride for injection1 mcg/kg/min and subjects in the fentanyl group received a bolus loading dose of 15 mcg/kg and placebo continuous infusion. During maintenance, supplemental bolus doses of Remifentanil Hydrochloride for injection (0.5 mcg/kg) and infusion rate increases of 0.5 to 1 mcg/kg/min (maximum rate allowed was 4 mcg/kg/min) of Remifentanil Hydrochloride for injection were administered to one group; while the fentanyl group was given intermittent maintenance bolus doses of 2 mcg/kg and increases in the placebo infusion rate.

In these two studies, using a high dose opioid technique with Remifentanil Hydrochloride for injection as a component of a balanced or total intravenous anesthetic regimen, the remifentanil regimen effectively attenuated response to maximal sternal spread generally better than the dose and regimen studied for the active control (fentanyl). While this provides evidence for the efficacy of remifentanil as an analgesic in this setting, caution must be exercised in interpreting these results as evidence of superiority of remifentanil over the active control, since these studies did not make any attempt to evaluate and compare the optimal analgesic doses of either drug in this setting.

14.6 Neurosurgery

Remifentanil Hydrochloride for injection was administered to 61 patients undergoing craniotomy for removal of a supratentorial mass lesion. In these studies, ventilation was controlled to maintain a predicted PaCO2 of approximately 28 mmHg. In one study (n = 30) with Remifentanil Hydrochloride for injection and 66% nitrous oxide, the median time to extubation and to patient response to verbal commands was 5 minutes (range -1 to 19 minutes). Intracranial pressure and cerebrovascular responsiveness to carbon dioxide were normal [see Clinical Pharmacology (12.2)].

A randomized, controlled study compared Remifentanil Hydrochloride for injection (n = 31) to fentanyl (n = 32). Remifentanil Hydrochloride for injection (1 mcg/kg/min) and fentanyl (2 mcg/kg/min) were administered after induction with thiopental and pancuronium. A similar number of patients (6%) receiving Remifentanil Hydrochloride for injection and fentanyl had hypotension during induction. Anesthesia was maintained with nitrous oxide and Remifentanil Hydrochloride for injection at a mean infusion rate of 0.23 mcg/kg/min (range 0.1 to 0.4) compared with a fentanyl mean infusion rate of 0.04 mcg/kg/min (range 0.02 to 0.07). Supplemental isoflurane was administered as needed. The patients receiving Remifentanil Hydrochloride for injection required a lower mean isoflurane dose (0.07 MAC-hours) compared with 0.64 MAC-hours for the fentanyl patients (P = 0.04). Remifentanil Hydrochloride for injection was discontinued at the end of anesthesia, whereas fentanyl was discontinued at the time of bone flap replacement (a median time of 44 minutes before the end of surgery). Median time to extubation was similar (5 and 3.5 minutes, respectively, with Remifentanil Hydrochloride for injection and fentanyl). None of the patients receiving Remifentanil Hydrochloride for injection required naloxone compared to seven of the fentanyl patients (P = 0.01). Eighty-one percent (81%) of patients receiving Remifentanil Hydrochloride for injection recovered (awake, alert, and oriented) within 30 minutes after surgery compared with 59% of fentanyl patients (P = 0.06). At 45 minutes, recovery rates were similar (81% and 69% respectively for Remifentanil Hydrochloride for injection and fentanyl, P = 0.27). Patients receiving Remifentanil Hydrochloride for injection required an analgesic for headache sooner than fentanyl patients (median of 35 minutes compared with 136 minutes, respectively [P = 0.04]). No adverse cerebrovascular effects were seen in this study [see Clinical Pharmacology (12.2)].

14.7 Continuation of Analgesic Use into the Immediate Postoperative Period

Analgesia with Remifentanil Hydrochloride for injection in the immediate postoperative period (until approximately 30 minutes after extubation) was studied in 401 patients in four dose-finding studies and in 281 patients in two efficacy studies. In the dose-finding studies, the use of bolus doses of Remifentanil Hydrochloride for injection and incremental infusion rate increases ≥ 0.05 mcg/kg/min led to respiratory depression and muscle rigidity.

In two efficacy studies, Remifentanil Hydrochloride for injection0.1 mcg/kg/min was started immediately after discontinuing anesthesia. Incremental infusion rate increases of 0.025 mcg/kg/min every 5 minutes were given to treat moderate to severe postoperative pain. In Study 1, 50% decreases in infusion rate were made if respiratory rate decreased below 12 breaths/min and in Study 2, the same decreases were made if respiratory rate was below 8 breaths/min. With this difference in criteria for infusion rate decrease, the incidence of respiratory depression was lower in Study 1 (4%) than in Study 2 (12%). In both studies, Remifentanil Hydrochloride for injection provided effective analgesia (no or mild pain with respiratory rate ≥ 8 breaths/min) in approximately 60% of patients at mean final infusion rates of 0.1 to 0.125 mcg/kg/min.

Study 2 was a double-blind, randomized, controlled study in which patients received either morphine sulfate (0.15 mg/kg administered 20 minutes before the anticipated end of surgery plus 2 mg bolus doses for supplemental analgesia) or Remifentanil Hydrochloride for injection(as described above). Emergence from anesthesia was similar between groups; median time to extubation was 5 to 6 minutes for both. Remifentanil Hydrochloride for injection provided effective analgesia in 58% of patients compared to 33% of patients who received morphine. Respiratory depression occurred in 12% of patients receiving Remifentanil Hydrochloride for injection compared to 4% of morphine patients. For patients who received Remifentanil Hydrochloride for injection morphine sulfate (0.15 mg/kg) was administered in divided doses 5 and 10 minutes before discontinuing Remifentanil Hydrochloride for injection. Within 30 minutes after discontinuation of Remifentanil Hydrochloride for injection the percentage of patients with effective analgesia decreased to 34%.

14.8 Monitored Anesthesia Care

Remifentanil Hydrochloride for injection has been studied in the monitored anesthesia care setting in 609 patients in eight clinical studies. Nearly all patients received supplemental oxygen in these studies. Two early dose-finding studies demonstrated that use of sedation as an endpoint for titration of Remifentanil Hydrochloride for injection led to a high incidence of muscle rigidity (69%) and respiratory depression. Subsequent trials titrated Remifentanil Hydrochloride for injection to specific clinical endpoints of patient comfort, analgesia, and adequate respiration (respiratory rate > 8 breaths/min) with a corresponding lower incidence of muscle rigidity (3%) and respiratory depression. With doses of midazolam > 2 mg (4 to 8 mg), the dose of Remifentanil Hydrochloride for injection could be decreased by 50%, but the incidence of respiratory depression rose to 32%.

The efficacy of a single dose of Remifentanil Hydrochloride for injection (1.0 mcg/kg over 30 seconds) was compared to alfentanil (7 mcg/kg over 30 seconds) in patients undergoing ophthalmic surgery. More patients receiving Remifentanil Hydrochloride for injection were pain free at the time of the nerve block (77% versus 44%, P = 0.02) and more experienced nausea (12% versus 4%) than those receiving alfentanil.

In a randomized, controlled study (n = 118), Remifentanil Hydrochloride for injection 0.5 mcg/kg over 30 to 60 seconds followed by a continuous infusion of 0.1 mcg/kg/min, was compared to a propofol bolus (500 mcg/kg) followed by a continuous infusion (50 mcg/kg/min) in patients who received a local or regional anesthetic nerve block 5 minutes later. The incidence of moderate or severe pain during placement of the block was similar between groups (2% with Remifentanil Hydrochloride for injection and 8% with propofol, P = 0.2) and more patients receiving Remifentanil Hydrochloride for injection experienced nausea (26% versus 2%, P < 0.001). The final mean infusion rate of Remifentanil Hydrochloride for injection was 0.08 mcg/kg/min.

In a randomized, double-blind study, Remifentanil Hydrochloride for injection with or without midazolam was evaluated in 159 patients undergoing superficial surgical procedures under local anesthesia. Remifentanil Hydrochloride for injection was administered without midazolam as a 1 mcg/kg dose over 30 seconds followed by a continuous infusion of 0.1 mcg/kg/min. In the group of patients that received midazolam, Remifentanil Hydrochloride for injection was administered as a 0.5 mcg/kg dose over 30 seconds followed by a continuous infusion of 0.05 mcg/kg/min and midazolam 2 mg was administered 5 minutes later. The occurrence of moderate or severe pain during the local anesthetic injection was similar between groups (16% and 20%). Other effects for Remifentanil Hydrochloride for injection alone and Remifentanil Hydrochloride for injection /midazolam were: respiratory depression with oxygen desaturation (SPO2 < 90%), 5% and 2%; nausea, 8% and 2%; and pruritus, 23% and 12%. Titration of Remifentanil Hydrochloride for injection resulted in prompt resolution of respiratory depression (median 3 minutes, range 0 to 6 minutes). The final mean infusion rate of Remifentanil Hydrochloride for injection was 0.12 mcg/kg/min (range 0.03 to 0.3) for the group receiving Remifentanil Hydrochloride for injection alone and 0.07 mcg/kg/min (range 0.02 to 0.2) for the group receiving Remifentanil Hydrochloride for injection /midazolam.